# Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

> **NCT07029581** · PHASE2 · RECRUITING · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Lewy Body Dementia Psychosis

## Interventions

- **DRUG:** ACP-204
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07029581
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2028-02
- **Final completion:** 2028-03
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07029581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07029581, "Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07029581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*